Working the case: a specimen that cannot answer the question

Return to the request from the opening problem. The citrate tube is short filled and the same-draw CBC shows platelets 62 x10^9/L (reference range 150-400 x10^9/L), hemoglobin 8.1 g/dL (reference range 12.0-16.0 g/dL), and leukocytes 16.8 x10^9/L (reference range 4.0-11.0 x10^9/L). No platelet-function result is released from this draw.

The short fill is a rejection criterion on its own: it changes the ratio of citrate anticoagulant to blood, alters the calcium available for the reaction, and disqualifies the tube for light-transmission aggregometry, whole-blood impedance aggregometry, and cartridge P2Y12 testing regardless of the platelet count or the rest of the CBC. The low platelet count is a separate problem, an analytical signal limitation rather than a rejection criterion in itself: a count this low can independently reduce or destabilize the aggregation signal in light-transmission aggregometry and in whole-blood impedance aggregometry, so a blunted result from an otherwise valid specimen could reflect too few platelets rather than a drug effect. The low hemoglobin and elevated leukocyte count are interpretive confounders, not independent grounds for rejection: anemia and hematocrit materially affect whole-blood impedance aggregometry and other shear-dependent platelet tests, and a markedly elevated leukocyte count can likewise alter a whole-blood signal, so a properly collected specimen with these findings still needs that biological context weighed before a result is read as reflecting drug effect rather than the patient's hematologic state.

The correct first action is to follow the local specimen-rejection and recollection policy: reject the short-filled tube, document the reason and the medication and collection timing, and request a properly collected specimen before any platelet-function method is run. A normal platelet count or a normal PT/aPTT would not repair this specimen and would not answer the ADP-pathway question either.

If a correctly collected specimen had been tested by a locally validated LTA procedure: ADP 5 umol/L gives maximal aggregation of 58%, within the laboratory's local adult interval of 55-85%; arachidonic acid 1 mmol/L gives maximal aggregation of 6%, below the local adult interval of 65-95%.

This pattern, preserved ADP response with reduced COX-1-pathway response, could be compatible with an aspirin effect and an intact P2Y12 pathway. It cannot, by itself, distinguish a missed clopidogrel dose from altered drug exposure, an interacting medication, inflammation, an inherited platelet-function defect, or ordinary analytical variation. It cannot direct a treatment change. It documents what the ADP and arachidonic-acid agonist responses looked like under the stated method and conditions, nothing more.

An aggregation result is only as valid as the specimen that produced it, and even a valid result answers a narrower question than a clinician might assume it does.